? NUTRIENT AND PHYTOCHEMICAL ANALYTICS SHARED RESOURCE (NPASR) The mission of the NPASR is to provide niche services supporting research with high quality assays for biomarkers of tobacco exposure, specific nutrients, or a vast array of anti-cancer phytochemicals found in food sources. NPASR primarily supports the Molecular Carcinogenesis and Chemoprevention (MCC) and the Cancer Control (CC) Programs, which have robust research examining the role of diet and tobacco in cancer etiology, prevention, and survivorship. The NPASR co-Directors are Drs. Steven Clinton, a translational researcher in cancer prevention (interim co-Director, Senior Faculty Advisor; MCC co-Leader) and Devin Peterson, a senior food science chemist in the College of Food, Agricultural, and Environmental Sciences.
The Specific Aims of the NPASR are to: 1) provide expert, leading-edge bioanalytical method development and quantitative analysis of nutrients and bioactive phytochemicals in foodstuffs; 2) conduct targeted quantitative analysis of nutrients, bioactive phytochemicals and their metabolites in biological samples generated from in vitro, in vivo and human studies using HPLC-MS/MS techniques; and 3) perform untargeted metabolomics and lipidomics services for cancer-related studies. NPASR technologies include state-of-the-art ultra-high performance liquid chromatography (UHPLC), mass spectrometry (MS) and liquid chromatography triple quadrupole MS/MS (LC- MS/MS). NPASR has added several new analytical capabilities during the current funding cycle including: 1) ion mobility hardware facilitating a broad semi-quantitative lipidomics platform; 2) a second MS instrument to support untargeted metabolomics and lipidomics demand; and 3) a state-of-the-art MS/MS for utmost sensitivity. During the current funding cycle, the NPASR supported 49 publications (2 > 10 impact factor), 55 users, and 6 NCI grants, including 1 P50, 3 R01s, 1 U19 and 1 U01, involving all five CCC programs. These efforts and publications have contributed to defining biomarkers of exposure or intake, and provided novel insight into phytochemical absorption, distribution, metabolism, and excretion. More recently, NPASR has expanded into targeted and untargeted metabolomics supporting our understanding of individual cancer risk due to tobacco exposure, nutrients, specific foods, and dietary patterns. To meet future demands of OSUCC Investigators aligned with OSUCCC strategic priorities, NPASR will further support, for example, studies of metabolomic- microbiome interactions, genetic determinants of metabolism and tobacco use biomarkers. During the next grant cycle, lipidomics and bioactive lipid analytic capabilities will be expanded to meet the needs of a growing user base of all five programs. The NPASR provides a critical service for CCC members evaluating foods, nutrients and carcinogens that spans research disciplines from cell culture and experimental animal studies to human trials and molecular epidemiology. The annual budget of the NPASR is $387,249, yet the CCSG request is $74,239. As such, the NPASR leverages extensive institutional support and seeks only 19.2% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090015
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications